NICE issues draft guidance for use of remdesivir and also for tixagevimab-cilgavimab for treatment of COVID-19

Draft guidance for public consultation has been published by the National Institute for Health and Care Excellence (NICE).

The recommendations are draft and could change following public consultation.

SMC has had direct input into the decision-making committee that produced the draft guidance. The final published advice will have the same status for health board consideration as other SMC advice on new medicines.

The draft guidance is open for public consultation until 8 February 2024. Anyone with an interest in this topic is encouraged to send their comments on the draft recommendation. Visit the NICE website to access the draft recommendation and to comment: Consultation | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] | Guidance | NICE